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The use of Breast-MRI in surgical planning of breast cancer is a field of controversy due to 
its high sensitivity but low specificity, alongside with overestimation of tumor-size. It has 
been proven many factors contribute to this overestimation. This study aims to define the 
extent of impact that the Clinical T-Stage, Histologic Subtype, Histologic Grade and 
Biologic Profile have on the correlation between MRI and ultrasonography (US) with 
pathology-measured tumor-size. To do so, a prospective, observational, descriptive, 
multicenter correlational study will be conducted in 145 women with recently diagnosed 
breast cancer, to whom a gadolinium-enhanced breast MRI will be performed alongside 
traditional triple assessment, recording largest diameter of tumor by US and MRI. This 
correlation will later be analyzed under the influence of the items in study individually to 
extract conclusions of the degree of impact, to secondly conjecture a mathematical model of 
optimization in tumor-size estimation. 
El uso de Resonancia Magnética Mamaria (RMM) en la planificación pre-quirúrgica del 
cáncer de mama es controvertido dada la alta sensibilidad y baja especificidad, junto con la 
sobreestimación del tamaño tumoral. Ha sido demostrado que múltiples factores 
contribuyen a  esta sobreestimación. Este estudio se centra en definir el grado de impacto 
que tienen la T-Clínica, Subtipo Histológico, Grado Histológico y Perfil Biológico sobre la 
correlación del tamaño tumoral medido por RMM o Ecografía y anatomía patológica. Se 
realizará un estudio prospectivo, observacional, descriptivo, correlacional y multicéntrico 
con 145 mujeres recientemente diagnosticadas de cáncer de mama, a las que se les 
realizará una MRR con gadolinio además del protocolo diagnóstico habitual, anotando el 
diámetro máximo de tumor observado en MRR y ecografía. Esta correlación será analizada 
bajo la influencia de los ítems a estudio individualmente para extraer conclusiones sobre el 
grado de impacto, para secundariamente desarrollar un modelo matemático de 
optimización en estimación de tamaño tumoral. 
KEYWORDS 
Magnetic Resonance Imaging. MRI. Breast Cancer. Concordance. Discordance. Tumor Size. 
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Breast cancer is diagnosed globally thanks to triple assessment (TA), a strategy that includes 
clinical examination, imaging techniques such as mammography and ultrasound (US), and 
pathological examination from biopsy. After diagnosis, therapeutic decisions have to be 
taken, and there is consensus on the use of breast conserving therapy after strong evidence of 
its benefits. The objective of this approach is to completely remove the tumor but affecting 
as least as possible aesthetics, due to the psychologic impact this can have on the patient. (1) 
Since the discovery of Magnetic Resonance Imaging (MRI), many uses have been 
discovered for this technique. Breast MRI has shown to be highly sensitive, and can identify 
foci of cancer that are not evident by TA. Although it has been traditionally defended that 
MRI improves selection of patients for breast conserving surgery, the COMICE study 
recently showed no significant reduction in reoperation rate by adding MRI to TA, 
suggesting this technique might be unnecessary in preoperative planning(2). This may very 
well be due to the overestimation in tumor-size, which increases the aggressiveness of 
therapeutic approach, combined with the fact that old guidelines have been directly applied 
instead of adapting new ones to MRI technology.  
Tumor size is one of the most important factors in determining disease-free and cause-
specific survival rates in invasive breast cancer, particularly in cases of node-negative breast 
cancers where tumor size becomes of utmost importance in determining type and extent of 
subsequent surgical and oncological management. This is well represented by The American 
Joint Committee on Cancer (AJCC) for Breast Tumors, where these are classified according 
to size (T1 >2cm, T2 2-5cm, T3 >5cm). Therefore, accurate measurement of an invasive 
breast cancer is crucial for allowing the best outcome in patient management. (3) 
Not many studies have been conducted studying the correlation of MRI and US with 
pathology-measured tumor size. The main referents in this area include the MONET(4) and 
the COMICE(2) studies. Since both conclude that further investigation is necessary in this 
field, this study aims to focus in different factors that alter the accuracy of these techniques 
for tumor-size estimation, to posteriorly conjecture a mathematical model for correction that 
can be used to optimize resources. 
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BREAST CANCER 
Breast cancer is the most frequently diagnosed cancer in women, accounting for as much as 
23% of all cancers, as well as the leading cause of cancer death among females, responsible 
of 14% of these. Furthermore, there is a global increasing incidence rate (nowadays, one in 
every 9-12 woman will develop a breast cancer), but fortunately followed by a decreasing 
annually mortality rate, partly due to the implantation of screening programs through 
mammographies and auto-palpation of breasts, leading to higher prevalence associated to 
longer survival rates.(1)  
Many factors have been traditionally said to be involved in the neogenesis of these tumors, 
among which are: immunologic, physical, chemical, environmental, hormonal, genetic, and 
alimentary factors, and viral infections. In order to reduce incidence of breast cancer, these 
risk factors are to be aimed for. 
Once the tumor has developed, secondary prevention has to take place to increase survival 
rates of these patients. This is where screening programs come in handy, together with 
clinical examinations.   
BREAST LESION: ACTUATION PROTOCOL 
The actual diagnostic protocol consists of the triple assessment: clinical examination, use of 
imaging techniques, such as mammography and ultrasound, and pathology microscopic 
diagnosis from biopsy. Following these, a body-CT or Gammagraphy is performed to 
complete extension study. The introduction of a preoperative breast-MRI to this protocol is a 
field of discussion among experts that is nowadays subject of controversy. 
CLINICAL EXAMINATION RELEVANCE 
Clinical examination has proven to be key in the early diagnosis of breast cancer.  The most 
important aspects of clinical exploration are inspection and palpation.  
Through inspection, we can search for retractions in the breast contour, nipple alterations, 
dilated cutaneous veins, redness of the skin, infiltration and edema, and skin ulceration.   
Through a correct palpation, we can describe the tumor’s size, situation, contour, and 
consistency. An irregular contour with irregular edges should awake suspicion, as well as a 
stiff consistency and a decreased mobility.  
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MAMMOGRAPHY AND BI-RADS CLASSIFICATION 
Mammography is the most valid and widely-used radiologic technique for breast cancer 
screening, whose objective is to detect early stage cancer in asymptomatic women.  It gives 
valuable information for differentiating benign and malignant lesions. When a mass lesion is 
detected at mammography, the lesion is first evaluated for the regularity of its margins. High 
density, irregular margins and speculation are important findings for malignant lesion. Also, 
microcalcifications in a mass lesion should be evaluated carefully. Although proven to be 
very sensitive, it yields a 10% of false negatives, especially in very dense breasts, were an 
additional ultrasonography is recommended for higher sensibility. (5)  
The radiologic findings are grouped according to the BI-RADS classification (Breast 
Imaging Reporting And Data System), indicating how suspicious of benignancy or 
malignancy a lesion is.    
 
ULTRASONOGRAPHY 
Although mammography is a very effective method for detecting breast tumors, 
ultrasonography (US) is far more valuable in the screening of dense breasts(6). Furthermore, 
US is the election technique for differentiating cystic and solid masses. A cyst will appear as 
an anechoic lesion with regular margins, smooth walls, ovoid shape and with posterior 
acoustic enhancement.(5)  
A study published by W. Berg et.al describes US yielding higher sensitivity than did 
mammography for the detection of specific histological subtypes, such as Invasive Ductal 
Carcinoma (IDC) in 94% cases, and Invasive Lobular Carcinoma (ILC) in 86% cases. 
However, US involves risk of overestimation of tumor extent.(6)  
Moreover, Cortadellas et.al(7) concludes that ultrasonography is the best predictor of tumor 
size in breast cancer, when compared with clinical examination, mammography, and MRI, 
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GADOLINIUM ENHANCED-MRI IN PRE-SURGICAL EVALUATION 
The dynamic gadolinium-enhanced MRI is the auxiliary image technique of election of 
highest sensibility (88-100%) for breast cancer, although its limited specificity (22-97%) 
makes its use reserved for limited situations and always in combination with other imaging 
techniques. It is used in pre-surgical evaluation especially in the study of local extension, 
although its use is of big controversy, having some authors recommend its limitation to 
young woman with dense breasts.   
Nevertheless, some studies have shown MRI has a higher sensitivity than mammography for 





(9) This discords with the information recently published by Cortadellas 
(7), proving further investigation is necessary in this field. 
In nonfatty breasts, US and MRI have proven to be more sensitive than mammography for 
breast cancer detection, but both MR and US involve risk of overestimation of tumor extent. 
Finally, Berg concludes that combined mammography, clinical examination and MRI are 
more sensitive than any other individual test or combination of tests. (6) 
 
PATHOLOGY CLASSIFICATION 
According to pathological findings in the biopsy, and for the purpose of this investigation, 
we subdivide breast cancer into: 
IDC: INVASIVE DUCTAL CARCINOMA 
EIC: IDC WITH EXTENSIVE INTRADUCTAL CARCINOMA 
ILC: INVASIVE LOBULAR CARCINOMA 
DCIS: DUCTAL CARCINOMA IN SITU 
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BREAST MRI: CURRENT USE AND CONTROVERSY 
It is well established that MRI is by far superior to mammography in the detection of breast 
cancer. Due to its very high negative predictive value, MRI can be used to confidently 
exclude the presence of breast cancer, and, this, avoid unnecessary surgery. Furthermore, 
due to its high sensitivity, MRI can detect cancer in the ipsilateral and contralateral breast 
that is missed by mammography and clinical examination. For all these reasons, MRI is 
considered an integral part of the work up of patients who undergo breast-conserving 
treatment for breast cancer. However, MRI has only been adopted in clinical practice slowly. 
Reasons for this include high costs of MRI, frequency of false positives, and fear of 







Because MRI is so sensitive, it was assumed that preoperative MRI would estimate the 
extent of disease more accurately than conventional imaging, thereby improving surgical 
planning. However, data available has shown that preoperative MRI has not improved 
outcomes, overestimates the extent of disease, and has overall limited value. The COMICE 
trial showed no difference in the reoperation rate with or without the use of preoperative 
MRI. In addition, many women had mastectomies (27.6%) later proven not necessary in 
pathology. Furthermore, in a review of 1558 consecutive patients with invasive breast 
cancer and/or noninvasive breast cancer, MRI was not associated with an advantage to lower 














Mennella describes that the type of biopsy procedure and the time interval between biopsy 
and preoperative MRI are not independently associated to MRI-Pathology discordance. 
However, size, histology and margins of tumors do have an impact. It is still a matter of 
discussion up to what extent do these have an influence, as well as what other factors lead to 
discordance in tumor-size estimation. (8)  
Grimsby describes that breast MRI is concordant with pathologic tumor size within .5cm 
among 53% of patients. Among tumors overestimated by MRI, 65% had additional 
significant findings in the breast tissue around the main lesion: satellite lesions, ductal 
carcinoma in situ, and/or lymphovascular invasion(15) 
In a study conducted by Onesti, he describes that MRI and pathology tumor size were 
positively correlated (R=.650), but with an average overestimation by MRI of .63 cm (P 
<.0001). When stratified by MRI tumor size (<2.0 cm and >2.0 cm), a significant difference 
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was found only in tumors greater than 2.0 cm (average overestimation = 1.06 cm; P <.0001). 
This trend continued for the histological subtypes of ductal carcinoma in situ (DCIS), 
invasive ductal carcinoma (IDC), and invasive lobular carcinoma (ILC).(16) 
Therefore, we can see how tumor size and histologic subtype are indeed factors affecting the 
accuracy of MRI in tumor-size estimation, but further investigation in this area is needed.  
On a separate subject, it has been well-established in several studies that MRI is a highly-
recommended diagnostic tool for high-risk patients. These include: being a BRCA1 or 
BRCA2 mutation carrier or having a first-degree relative with these, receiving previous 
radiotherapy on the chest-wall, personal history of Li-Fraumeni or Cowden disease, or 
having an estimated lifetime risk of breast cancer of 20 percent or higher calculated with the 
BRCA-PRO model.  It is in order to mention that these patients are not the subject of this 




Also, this investigation aims to focus on Breast-MRI as part of the pre-surgical examination 
by analyzing factors that influence tumor-size appearance. This has to not be mistaken with 
the full body CT-Scan that patients undergo during the extension study. 
 
JUSTIFICATION OF STUDY AND OBJECTIVES 
Because MRI is so sensitive, it was assumed that preoperative MRI would estimate the 
extent of disease more accurately than conventional imaging, thereby improving surgical 
planning. However, available data has shown that preoperative MRI has not improved 
outcomes, overestimates the extent of disease and has overall limited value(1) 
It is thereby this study’s main objective to examine the correlation of MRI and US with 
Pathology-measured tumor size according to histologic subtype, histologic grade, clinical T-
stage, and Biologic profile (Estrogen receptors, Progesterone receptors, and Her2/Neu) in 
order to secondly conjecture a mathematical model of approximation to maximize precision 
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HYPOTHESIS 
Histologic subtype, Histologic grade, clinical T-stage and Biologic Profile are factors 
influencing US-Pathology and MRI-Pathology tumor-size correlation, thereby leading to an 
unnecessary amount of mastectomies (non-conservative breast therapies) in breast cancer 
management. Therefore, a correction of the impact of these factors by a mathematical model 
should lead to higher precision in tumor-size estimation with imaging techniques. 
METHODS AND MATERIALS 
DESIGN 
This is an observational, descriptive, prospective, multi-centric, correlational study with 145 
women with newly diagnosed, biopsy-proven, primary breast cancer who will be offered to 
enter the study, following a consecutive sampling, by undergoing a Breast Gadolinium 
Enhanced MRI before surgical treatment. Tumor-size measurements, excluding those 
obtained by MRI, will be obtained from the traditional triple assessment. In both cases, only 
the largest diameter of lesion size will be used to determine tumor size. Patients without a 
clear and precise measurement of the largest diameter of tumor size due to any reason will 
be excluded from the study. Cases in which neoadjuvant chemotherapy can’t be delayed to 
after the MRI has been performed will also be excluded, as this factor is a demonstrated 
source of discordance(15).  
SAMPLE SIZE NEEDED: CALCULATING N 




Zα: Z-value for Risk α; if α= 0.05, Zα= 1.960 
Zβ: Z-value for Risk β; if β = 0.01, Zβ= 2.326 
s
2
: known variance in control group  from Mennella: ?̅?=24.8 mm +/- 19.4 mm with 













= 138.27.  
If we assume a possible 5% loss (7 people), we can optimize for an N = 145 
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INCLUSION CRITERIA RECENTLY DIAGNOSED BREAST CANCER 
- >18 years old 
- No metastasis 
- Possibility to perform US and MRI 
EXCLUSION CRITERIA 
 Contraindications of MRI: including but not limited to 
o Patients with severe claustrophobia 
o Patients who have a Heart Pacemaker or an Implantable Cardioverter 
Defibrillator 
o Patients who have a metallic foreign body such as projectiles form firearms 
o Patient who have an aneurysm clip in their brain 
o Patients who have had metallic devices placed in their back (such as pedicle 
screws or anterior interbody cages) 
o Patients with cochlear implants 
o Patients with an Intrauterine Device (IUD) 
o Patients with orthopedic devices 
 Previous radiotherapy in chest-wall 
 Previous breast cancer in ipsilateral or contralateral breast 
 High-Risk Patient: including, but no limited to 
o BRCA1 or BRCA2 carrier 
o BRCA1 or BRCA2 1st 
degree case 
o Li-Fraumeni Syndrome 
o Cowden Syndrome 
o Peutz-Jegher Syndrome 
 Lynch Syndrome Patients with an active neoplasia other than the breast cancer 
 Patients with metastasis of unknown origin 
 Patients that are pregnant 
 Patients <18 years old 
 Renal Insufficiency or Nephrogenic Systemic Fibrosis, or Gadolinium allergy 
 Patients who need neoadjuvant chemotherapy that can’t be delayed until after the 
MRI has been performed 
 Patients without a clear and precise measurement of the largest diameter of tumor 
size due to any reason 
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DATA COLLECTION 
Since the purpose of this investigation is to analyze correlation of tumor-size according to 
multiple factors, the recollection of the following data is of crucial importance: 
- Size measured by Ultrasound (in mm) 
o Largest tumor diameter measured in US, recorded in millimeters.  
- Size measured by MRI (in mm) 
o Largest tumor diameter measured in MRI, recorded in millimeters. 
- Size calculated by Pathology (in mm) 
o Largest tumor diameter measured in pathology, recorded in millimeters. 
- Clinical T-Stage(18) (T1-T2-T3-T4): As defined by the American Joint Committee on 
Cancer. Pre-Surgical Evaluation. Record pertaining category 
o T1: Tumor ≤20 mm in its biggest dimension 
 T1a: 1mm ≤ tumor ≤ 5mm 
 T1b: 5mm < tumor ≤ 10mm 
 T1c: 10mm< tumor ≤ 20mm 
o T2: 20mm < tumor ≤ 50mm 
o T3: tumor > 50mm 
o T4: any tumor-size with one of the followings: 
 T4a: extension to thoracic-wall, not including pectoral muscle 
 T4b: edema (including orange-skin) or breast skin ulceration, or satellite 
lymph nodes of the skin limited to the same breast 
 T4c: both T4a and T4b combined 
 T4d: Inflammatory carcinoma 
- Histologic Subtype(13) (IDC, EIC, ILC, DCIS, Other): Record pertaining category. For 
the purpose of this investigation, classification is as follows: 
o IDC: INVASIVE DUCTAL CARCINOMA 
o EIC: IDC WITH EXTENSIVE INTRADUCTAL CARCINOMA 
o ILC: INVASIVE LOBULAR CARCINOMA 
o DCIS: DUCTAL CARCINOMA IN SITU 
o “OTHER HISTOLOGY”: Mucinous, papillary, medullary, tubular and apocrine 
breast cancer; or any histology that doesn’t fit the previous categories. 
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- Histologic Grade/ Nottingham Score (18) (19) (G1/G2/G3): Post-Surgical Evaluation. 
Record pertaining category. In this scoring system, three factors are taken into 
consideration by pathologists:  
o Glandular (Acinar) / Tubular Differentiation 
 Score 1: >75% of tumor area forming glandular/tubular structures 
 Score 2: 10% to 75% of tumor area forming glandular/tubular structures 
 Score 3: <10 of tumor area forming glandular/tubular structures 
o Nuclear Pleomorphism 
 Score 1: Nuclei small with little increase in size in comparison with normal 
breast epithelial cells, regular outlines, uniform nuclear chromatin, little 
variation in size 
 Score 2: Cells larger than normal with open vesicular nuclei, visible 
nucleoli, and moderate variability in both size and shape. 
 Score 3: Vesicular nuclei, of the with prominent nucleoli, exhibiting marked 
variation in size and shape, occasionally with very large and bizarre forms 
o Mitotic Count: using a high power filed diameter of 0.50mm 
 Score 1: ≤7 mitoses per 10 high power fields 
 Score 2: 8-14 mitoses per 10 high power fields 
 Score 3:  ≥15 mitoses per 10 high power fields 
Each of these features is scored from 1-3, and then each score is added to give a final 
score, which is classified as: 
o Grade 1 (G1): score of 3, 4 or 5 
o Grade 2 (G2): score of 6 or 7 
o Grade 3 (G3): score of 8 or 9 
 
- Biologic Profile (E, Pg, Her2/Neu, Ki67): Record if positive or negative  
o Estrogen Receptors (E): Positive if result shows >10%. Negative otherwise. 
Record the % in the comment box.  
o Progesterone Receptors (P): Positive if result shows >10%. Negative otherwise. 
Record the % in the comment box. 
o Her2/Neu: Record if positive or negative result. 
o Ki67: Record if positive or negative result. 
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Nevertheless, the following information shall also be recorded for possible further analysis: 
- Age of patient (in years old) 
- Reproductive age versus Menopause  
- Presence of microcalcifications (yes/no) 
- Lymph Node Invasion (20): Number and localization of lymph nodes affected (N-
factor of TNM) as defined by the American Joint Committee on Cancer (pNX, pN0, 
pN0(i-), pN0 (i+), pN1mi, pN1a, pN2a, pN3a). 
All of these data will be collected into a predefined table that can be found as an attachment 
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CHRONOLOGY 
1. Informative meeting with professionals willing to participate in the investigation. This 
meeting will serve as an opportunity to explain the study, thoroughly go through every 
step of the investigation and resolve any doubts rising from the protocol. 
2. Patient recently diagnosed with breast cancer thanks to Triple Assessment. In this step, 
the patient is identified as suitable for the investigation and proposed to enter the study. 
Check for inclusion and exclusion criteria. If met, explain study and give “information 
to the patient document” (see attachment 3 in page 26). If the patient accepts, signal of 
informed consent document. Record filiation data, and submit information to project 
manager. If all criteria is met, an identification number will be assigned to the patient. 
3. Collection of data: Start to collect the data as indicated in Table 1 (see attachment 1 in 
page 24). In this step, the following should be collected: Age, Reproductive Stage, Size 
by Ultrasound (obtain information from medical history, as this is part of triple 
assessment. In case this information is not available, another US is necessary), Clinical 
T-Stage, Histologic Subtype, Biologic Profile, Histologic Grade, Presence of 
microcalcifications, Lymph Node Invasion.  
4. Patient receives Breast-MRI with Gadolinium contrast. The tumor-size in MRI is 
recorded in the patient’s collection data table. 
5. Patient undergoes surgery as part of the normal treatment (independently of Breast MRI 
result) 
6. Biologic specimen analyzed in pathology lab. Once results are available, record: tumor-
size measured by pathology. 
7. Once there is information collected for 145 patients, researchers perform statistical 
analysis of data.  
8. Extracting conclusions, and attempting to conjecture the mathematical model through 
the inclusion of correcting factors leading to tumor-size discordance between 
techniques.  
In order to make this information more clear visually, Table 2 is available in the 
attachments. (See Attachment 2 in page 25)
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STATISTICAL ANALYSIS 
Categorical data will be expressed as number and percentage, while continuous data as mean 
and standard deviation. The normal distribution of MRI, US and pathology measurements 
will be assessed using D’Agostino-Pearson test in each factor examined (histologic subtype, 
clinical T, histologic grade and biologic Profile), comparing separately MRI vs Pathology 
and US vs Pathology for each category examined. Since some data-sets don’t follow normal 
distribution (e.g. tumor size in the different histologic subgroups), non-parametric tests will 
be used instead of parametric ones. The degree of relationship between two independent 
variables will be determined by using the Sperman’s rank correlation.  
Concordance between MRI or US and Pathology tumor-size is defined as a difference of 
≤5mm.  
Mann-Whitney test will be used to assess the difference between the medians of two 
independent groups, and Kruskal-Wallis test to verify the presence of a statistically 
significant difference between the medians of more than two different groups. After a 
positive Kruskal-Wallis test (p<0.05), a post-hoc analysis will be conducted performing 
pairwise comparison of subgroups. 
Bland-Altman analysis will be used to determine to what extent the MRI or US tumor size 
correlates with the four main factors. 
In addition, the absolute difference between MRI and Pathology measurements will be 
calculated, and the presence (or absence) of MRI-pathology discordance (difference >5mm) 
will be put as a dichotomous dependent variable in a multivariate logistic regression model, 








 Page 17 of 28 
 
ESTIMATED BUDGET 
In order to calculate the estimated budget for this investigation, the following are 
considered: 
 Price/Unit (€) Number of Units Total Price (€) 
Gadolinium Enhanced 
Breast-MRI 
175 145 25.375 
Materials (Paper, Binders, 
Staplers, Printer Ink…) 
10 145 1450 
Statistics Consulting 300 - 300 
Extra Emergency Burden 500 - 500 
    
TOTAL   27.625 
It is in order to mention that the following are not considered direct costs of this 
investigation: Monetary compensation for participants or researchers, economic cost derived 
from triple assessment (as this is performed independently to the investigation), and 
transportation costs.
EXPECTED RESULTS AND PRACTIC APPLICATIONS   
With this correlational study we aim to define the amount of impact the factors investigated 
have on the correlation between MRI and US with Pathology-measured tumor size. We have 
therefore chosen the factors based on strong believe that these yield real alteration on the 
response variable, thus expecting to find the actual extent of influence they have. The four 
main variables we expect to see as influencers are clinical T-stage, Histologic subtype, 
Histologic Grade and Biologic Profile. The secondary variables collected (age, reproductive 
stage, lymph node invasion) we believe will have a smaller impact on the distortion of 
correlation. Furthermore, US and MRI-measured size will both have to be taken into 
consideration when pursuing the secondary objective of this investigation, which is to 
conjecture a mathematical model of approximation to optimize size estimation. This model 
will then have to be tested in future studies to verify for reliability. If proven to be reliable, 
we believe this model should be implemented into clinical practice in order to achieve the 
maximum level of accuracy, and thus indicate conserving breast therapy with less margin of 
error. 
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LIMITATIONS OF STUDY 
As in any scientific investigation, this study presents several limitations.
The first limitation is common to all kinds of studies: aleatory error. This is defined as the 
lack of precision caused by arbitrariness. This error doesn’t affect the internal validity but 
decreases the precision of the investigation. A solution to minimize this error is to increase 
the sample size studied, but this also derives in an increases budget. 
Secondly, it is a correlating investigation, and thus is encumbered by all the limitations of 
such design. These include, but are not limited to, the lack of temporal sequence, the 
inability to control confounding factors, and the fact that a lack of correlation might not 
mean a lack of association. 
 
Specifically linked to this investigation, the following are sources of limitation: 
· Measurement of the larget tumor diameter by different radiologists might leed to small 
diferences. This is one of the points to discuss in the staff meeting prior to starting the study. 
Also, a Kappa Test could be perfomed to analyze the magnitude of impact of this error. This 
error is tried to combat by excluding from the study those cases with significant controversy 
· There is technical complexity in obtaining an accurate measurement of DCIS lesions at 
pathological analysis of surgical specimens (as previously reported by other studies” 
· Investigator influence during the malignancy assesment of the results due to previous 
knowledge of the results with other imaging techniques cannot be excluded. 
· There is always a selection bias, as woman are subjectively selected for the investigation. 
· Pathology is defined in this study as the gold standard. Thus, our study includes all the 
limitations inherent to today’s standards for pathology 
· The low prevalence of certain hystologic subtypes leads to a smaller precision estimation 
of the impact this factor has on tumor-size correlation. 
· There are many items that could be playing as confounding factors, that are not taken into 
consideration by this investigation.  
· Due to the high quantity of exclusion criteria, external validity might be compromised.  
However, it is important to mention that in order to reassure the highest level of quality, and 
in order to reduce confusion, previous to publishing this investigation, a thorough 
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reevaluation will be carried out using the 22-item check-list defined in the STROBE 
Declaration for Observational Studies. 
 
CONFLICT OF INTERESTS 
The author has no conflicts of interest to declare. 
 
ETHICAL STATEMENT 
The study will have to go through the ethical committee of all centers participating in the 
investigation, although no denials are assumed due to the safety associated with magnetic 
resonance, and especially due to the exclusion of patients who could detriment from 
gadolinium use. 
 
DIFFUSION MECHANISMS  
The main diffusion mechanism planned for this investigation is the publication of the study 
in Acta Radiologica (SAGE Journals), the leading journal in the ambit of imaging 
techniques. It is also the journal that holds most of the previous articles linked to this 
investigation, thus contributing to the development of knowledge in this field.  
Publication in other scientific journals may also be contemplated, especially those 
concerning specifically breast cancer, and radiologic journals. These include: 
· Advances in Breast Cancer Research (ISSN: 2168-1597) 
· Global Journal of Breast Cancer Research (ISSN: 2309-4419) 
·Nature Partner Journals (NPJ) Breast Cancer (ISSN: 2374-4677) 
·International Journal of Breast Cancer (ISSN: 2090-3189) 
·The Breast Journal (ISSN: 1524-4741) 
·The Breast: Official Journal of the European Society of Mastology (ISSN: 1532-3080) 
· Breast Cancer Research and Treatment (ISSN: 1573-7217) 
· The Lancet (ISSN: 0140-6736) 
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· European Journal of Cancer (ISSN: 0959-8049) 
· The New England Journal of Medicine (ISSN: 0028-4793) 
· European Journal of Radiology (ISSN: 0720-048X) 
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ATTACHMENTS 
ATTACHMENT 1: TABLE FOR COLLECTION OF DATA 
TABLE 1: DATA COLLECTION 
            AGE  
  
  (years old) 
      
            REPRODUCTIVE STAGE Premenopausia 
 
Menopause 
    
            SIZE IN ULTRASOUND    (mm) 
      
            SIZE IN MRI 
 
  (mm) 
      
            SIZE IN 
PATHOLOGY  (mm)       
            



























    








Pg (+) (-) 
            





Ki67 (+) (-) 
            MICROCALCIFICATIONS  YES 
 
NO 
      












            










Insert number for AGE, SIZE IN ULTRASOUND, SIZE IN MRI and SIZE IN PATHOLOGY. Circle the best-
fitting option for all the others. Write percentages of biologic profile and any additional comments if 
necessary in the box available. 
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ATTACHMENT 2: TABLE OF CHRONOLOGY FOR DATA COLLECTION
 
TABLE 2. Chronogram of Data Collection 
 DATA 
COLLECTION 
#1: Once the 
patient is 
assigned an ID 














AGE X   
REPRODUCTIVE STAGE X   
SIZE IN US X   
SIZE IN MRI  X  
SIZE IN PATHOLOGY   X 
CLINICAL T-STAGE X   
HISTOLOGIC SUBTYPE X   
HISTOLOGIC GRADE X   
BIOLOGIC PROFILE X   
MICROCALCIFICATIONS X   
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ATTACHMENT 3: INFORMED DOCUMENT FOR THE PATIENT & INFORMED 
CONSENT 
INFORMATION DOCUMENT FOR THE PATIENT 
Correlation between Ultrasonography and Magnetic Resonance Imaging with Pathology-Measured 
Tumor Size in Women with Recently Diagnosed Breast Cancer: Optimizing tumor-size estimation 
with imaging techniques for higher precision.
 
Dear patient, 
The objective of this document is to briefly and clearly explain the purpose of the study in which we 
offer you to participate. This document might contain words you don’t understand, in which case we 
strongly urge you to not hesitate to ask the specialists involved in the study for explanations. When 
you have completely understood all the information presented, and if you are willing to participate, 
we will kindly ask you to sign an informed consent document. 
The study we are conducting has as main objective analyze the correlation existing between real 
tumor-size calculated in pathology after surgical extraction and preoperative estimation by means of 
imaging techniques such as ultrasound (US) and magnetic resonance (MRI), and to what extent 
different factors contribute to an increasing discordance. This way, we pretend to later conjecture a 
mathematical model that takes into consideration these factors and helps in the decision process of 
therapeutic approximation to breast cancer, hoping always for breast conservation therapy, meaning 
surgery that is minimally invasive without compromising security.  This is why we kindly ask you to 
participate in the study, which only means that you will undergo a MRI scan previous to any possible 
surgery.  
Leaving the study 
Your participation in this study is completely voluntary, meaning you are free to leave the study at 
any moment of the investigation, without having to give any particular reason. Also, leaving the 
study will not compromise your treatment or future medical attention in any way. 
Your doctor can also dismiss you from the study at any given time if he/she considers it best for you, 
or if you don’t meet the requisites to participate. You could be dismissed from the study if it is 
considered that you could be harmed in any way, if you need any treatment not allowed by this 
study, if you don’t follow the instructions given for the study, if you get pregnant during the study or 
if the study is canceled. 
Possible Risks and Inconveniences 
The possible risks associated with this study are those associated with the practice of an MRI Scan, 
none of which are different of those associated to MRI in common practice. 
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Confidentiality 
Your medical history and biologic data will be accessed keeping the most precautious and strict 
confidentiality in a way that does not violate personal privacy. Your data will be codified so that the 
information obtained won’t identify you directly. This way you will not be able to be identified 
during the analysis and presentation of the results in publications related to this study. You are 
guaranteed the strictest compliance with the Law of Protection of Personal Data (Spain: Ley 15/1999 
de Diciembre de Protección de Datos Personales) 
If you accept to participate in this study, you authorize the access to your medical history not only by 
your doctor and team, but also by the staff involved in the development of this study (Study 
promoter) and the Regulatory Health Authorities  
Monetary Compensation 
There is no monetary compensation for the possible expenses incurred in the fulfillment of requisites 
of the study, such as transportation, nor for participating in this study.  
Results 
Once the study is completed and the results are available, your doctor can inform you if you wish. If 
the study results are published and you are interested in getting to know them, you will be given a 
copy of the publication or you will be given access to the results.
 
Acknowledgment: 
We would like to thank you for taking the time to read this document. Please take the time you need 
before deciding whether to participate in this study. If you finally decide to take part in the study, 
you are kindly asked to sign two copies of the informed consent and keep one of them. The other 
will remain on file in your medical record. If any doubts appear during the course of this 
investigation, or in case of any emergency, please don’t hesitate to contact the staff in charge.  
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INFORMED CONSENT DOCUMENT  
Correlation between Ultrasonography and Magnetic Resonance Imaging with Pathology-Measured 
Tumor Size in Women with Recently Diagnosed Breast Cancer: Optimizing tumor-size estimation 
with imaging techniques for higher precision. 
I have read the foregoing information, or it has been read to me. I have had the opportunity to ask 
questions about it and any questions that I have asked have been answered to my satisfaction. I 
consent voluntarily to participate as a participant in this research.  
I authorize the performance of a Magnetic Resonance in addition to the traditional triple assessment 
of breast cancer (including clinical examination, ultrasound imaging and/or mammography, and 
pathologic examination from biopsy-obtained tissue).  
Regarding the use of clinical information available in my medical history and of any biologic 
material left-over by the study:  
· I authorize the use of biologic materials and the clinical data associated with these for any further 
investigation, knowing this information will be treated anonymously.  
YES □         NO □ 
· I wish to be informed of important information derived from the investigation 
YES □         NO □ 
· I authorize to be contacted in the case of need of more information or biological samples.  
YES □         NO □ 
 
Print Name of Participant: _______________________________________________________ 
Date (DD/MM/YY): ___________________________________________________________ 
Signature of Participant:  
 
 
Print Name of Researcher: ________________________________________________________ 
Date (DD/MM/YY): ____________________________________________________________ 
Signature of Researcher:  
 
